CYDY · Cytodyn Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $0 | - | - |
| Cost of Revenue | - | - | - | $53.0K | - | - |
| Gross Profit | - | - | - | $213.0K | - | - |
| R&D | - | $7.24M | $2.63M | $27.04M | $58.43M | $52.64M |
| SG&A | $7.26M | $10.79M | $17.14M | $44.30M | $34.32M | $19.97M |
| Total Operating Expenses | ($9.66M) | $18.06M | $40.58M | $145.62M | $74.65M | $74.65M |
| D&A | $18.0K | $29.0K | $175.0K | $1.80M | - | $2.03M |
| Operating Income | $9.66M | ($18.06M) | ($40.58M) | ($145.40M) | ($104.60M) | ($74.65M) |
| Interest Expense | - | - | - | - | - | $18.22M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $3.75M | ($49.84M) | ($79.82M) | ($210.82M) | ($154.67M) | ($124.40M) |
| EPS - Basic | $0.00 | ($0.05) | ($0.10) | ($0.31) | - | - |
| EPS - Diluted | $0.00 | ($0.05) | ($0.10) | ($0.31) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.90M | $3.11M | $2.54M | $4.23M | $33.94M | $14.28M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | $0 | - | - | $93.48M | - |
| Accounts Payable | $14.69M | $29.56M | $62.73M | $67.97M | $65.90M | $29.48M |
| Current Assets | $17.88M | $10.81M | $10.80M | $10.52M | $129.58M | $36.83M |
| Total Assets | $18.05M | $11.14M | $11.29M | $29.18M | $132.08M | $50.51M |
| Current Liabilities | $70.52M | $84.18M | $119.80M | $123.16M | $152.55M | $44.50M |
| Long-term Debt | $45.35M | $45.02M | $45.73M | $42.22M | - | - |
| Total Liabilities | $114.09M | $127.89M | $120.79M | $123.58M | $153.10M | $52.99M |
| Stockholders' Equity | ($96.04M) | ($116.76M) | ($109.50M) | ($94.40M) | ($21.02M) | ($2.48M) |
| Retained Earnings | ($887.79M) | ($891.53M) | ($841.69M) | ($766.13M) | ($511.29M) | ($354.71M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.77M) | ($10.98M) | ($25.11M) | ($77.72M) | ($117.57M) | ($68.80M) |
| Investing Cash Flow | - | - | - | - | ($122.0K) | ($41.1K) |
| Financing Cash Flow | $10.85M | $11.75M | $29.93M | $48.01M | $137.35M | $79.67M |
| CapEx | - | - | - | - | $122.0K | $41.1K |
| Free Cash Flow | - | - | - | - | ($117.69M) | ($68.84M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 0.76 | 0.55 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | 0.0% | - | - | - | - | - |
| Return on assets | 20.8% | -447.6% | -706.9% | -722.4% | -117.1% | -246.3% |
| Return on equity | -3.9% | 42.7% | 72.9% | 223.3% | 735.9% | 5015.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.25 | 0.13 | 0.09 | 0.09 | 0.85 | 0.83 |
| Quick ratio | 0.25 | 0.13 | 0.09 | 0.09 | 0.24 | 0.83 |
| Cash ratio | 0.17 | 0.04 | 0.02 | 0.03 | 0.22 | 0.32 |
| Leverage | ||||||
| Debt / Equity | -0.47 | -0.39 | -0.42 | -0.45 | - | - |
| Debt / Assets | 2.51 | 4.04 | 4.05 | 1.45 | - | - |
| Debt / EBITDA | 4.69 | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -4.1x |
| Equity multiplier | -0.19 | -0.10 | -0.10 | -0.31 | -6.28 | -20.36 |
| Liabilities / Assets | 6.32 | 11.48 | 10.70 | 4.23 | 1.16 | 1.05 |
| Efficiency | ||||||
| Asset turnover | - | - | 0.00 | 0.00 | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | 468123d | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 55.5% | 72.1% | -39.0% | -40.1% | -33.7% |
| Net income growth (YoY) | - | 37.6% | 62.1% | -36.3% | -24.3% | -121.4% |
| EPS growth (YoY) | - | 50.0% | 67.7% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -71.0% | -36.4% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 17.7% | -6.6% | -16.0% | -349.1% | -747.3% | 72.2% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✓Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CytoDyn Inc. against the 5 most active filers in the same SIC group.